A Study of GC203 TIL in PDCA (RJ)

This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT ID
NCT06828328
Phase
EARLY_PHASE1
Sponsor
Shanghai Juncell Therapeutics
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • GC203 TIL
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • have done the tumor resection for gene-edited GC203 TIL production and successfully produced；
  • Age: 18 years to 70 years;
  • Histologically diagnosed as pancreatic ductal adenocarcinoma;
  • Expected life-span more than 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →